The 6 most recent market catalysts affecting $RNXT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 55
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
Ascendiant Capital analyst Edward Woo maintained a 'Buy' rating on RenovoRx and raised the price target from $14 to $14.5. This action signals continued analyst confidence in Renov…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
RenovoRx shares are trading higher after the company announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology.
This headline represents a significant positive catalyst for RenovoRx. The publication of pharmacokinetic and pharmacodynamic data, especially from a Phase III sub-study, lends cre…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 65
RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer
RenovoRx announced a Notice of Allowance from the USPTO for a patent application covering methods and apparatuses for delivering therapeutic materials for cancer treatment. This is…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est
RenovoRx (RNXT) has updated its financial outlook for fiscal year 2026, increasing its sales guidance from a range of $3.000 million-$4.000 million to $3.750 million-$4.250 million…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 85
RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate
RenovoRx (RNXT) announced Q2 results that significantly surpassed analyst expectations. The company reported adjusted EPS of $(0.05), beating the $(0.07) estimate, and sales of $90…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027
RenovoRx announced the completion of patient enrollment for its Phase 3 TIGeR-PaC study, a critical step in the development of its targeted pancreatic cancer therapy. This mileston…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.